Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study

Karina Dahl Steffensen*, Marianne Waldstrøm, Niels Pallisgård, Bente Lund, Kjell Bergfeldt, Jessica Wihl, Nina Keldsen, Christian Marth, Ignace Vergote, Anders Jakobsen

*Corresponding author

Research output: Contribution to journalJournal articleResearchpeer-review

18 Citations (Scopus)
Original languageEnglish
JournalInternational Journal of Gynecological Cancer
Volume23
Issue number1
Pages (from-to)73-80
Number of pages8
ISSN1048-891X
DOIs
Publication statusPublished - 1 Jan 2013

Keywords

  • EGFR inhibition
  • KRAS
  • Liposomal doxorubicin
  • Ovarian cancer
  • Platinum resistance

Fingerprint Dive into the research topics of 'Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study'. Together they form a unique fingerprint.

Cite this